CoChat

Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database

Open access

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecdotally described. Aims: the 2005–2018 European Medicines Agency (EMA) dataset of Adverse Drug Reactions (ADRs) was analyzed to identify and describe possible clozapine withdrawal- and misuse-/abuse-/dependence-related issues. Method: A descriptive analysis of clozapine-related ADRs was performed when available, data on ADRs’ outcome, dosage, and possible concomitant drug(s) were considered. Results: Out of 11,847 clozapine-related ADRs, some 599 (5.05%) were related to misuse/abuse/dependence/withdrawal issues, including 258 withdrawal-related (43.1%); 241 abuse-related (40.2%); and 80 intentional product misuse-related (13.3%) ADRs. A small number of overdose- and suicide-related ADRs were reported as well. Clozapine was typically (69.2%) identified alone, and most (84.7%) fatalities/high-dosage intake instances were reported in association with a history of substance abuse. Conclusions: Previous suggestions about the possibility of a clozapine discontinuation/withdrawal occurrence are here supported, but further studies are needed. However, the misuse/abuse cases here identified might be difficult to interpret, given the lack of studies highlighting the possible recreational use of clozapine. The high-dosage intake, fatal outcomes and clozapine/polydrug abuse issues reported here may, however, be a reason for concern.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/brainsci10020105

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Total Number of clozapine-related misuse, abuse, dependence, withdrawal cases reported to EudraVigilance (EV) per year (2005–June 2018).
Figure 1 Total Number of clozapine-related misuse, abuse, dependence, withdrawal cases reported to EudraVigilance (EV) per year (2005–June 2018).CC BY · PubMed Central
Figure 2 Dosages of clozapine reported to the EudraVigilance (EV) dataset of clozapine-related misuse, abuse, dependence, withdrawal ADRs.
Figure 2 Dosages of clozapine reported to the EudraVigilance (EV) dataset of clozapine-related misuse, abuse, dependence, withdrawal ADRs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Research works printed but not linked: 5

  1. Stahl S.M. Stahl’s Essential Psychopharmacology-Prescriber’s Guide 6th ed. Cambridge University Press Cambridge, UK 2017
  2. Aronson J.K. Clozapine Meyler’s Side Effects of Drugs (Sixteenth Edition): The International Encyclopedia of Adverse Drug Reactions and Interactions Elsevier Kidlington, UK 2016 443 477
  3. European Medicines Agency (EMA) ICH Guideline E2B (R3) on Electronic Transmission of Individual Case Safety Reports (ICSRs)—Data Elements and Message Specification—Implementation Guide Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-4.pdf (accessed on 25 July 2019)
  4. Bastiampillai T. Forooziya F. Dhillon R. Clozapine-withdrawal catatonia Aust. N. Z. J. Psychiatry 2013 43 283 284 19230235
  5. Ines S. Mahal A. Hoss J. Gaertner H.J. Intoxication with clozapine: Plasma levels above 9000 ng/mL. Typical clinical picture diagnostic confusion (abstract) Neuropsychopharmacology 1994 10 122S

Cited by

See all 35

Metadata

Authors
Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A.
Affiliations
  • University of Hertfordshire (GB)
  • Swansea University (GB)
Corresponding author
Schifano, Fabrizio
Venue
Brain Sciences
Publisher
MDPI AG
Published
2020-02-16
Volume
10
Issue
2
Pages
105
ISSN
2076-3425 (ISSN-L)
OpenAlex
W3005893007
Cited by
33
References
78
Citations by year
2026: 4 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 9 · 2020: 6
FWCI
4.05
Type
journal article
Language
en
Open access
Locations
  • Brain Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
clozapine, drug addiction, adverse drug reactions, pharmacovigilance, intentional drug overdose, suicide, substance abuse, polydrug abuse, treatment-resistant schizophrenia, recreational drug use

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. https://app.cochat.ai/papers/10.3390/brainsci10020105
The paper
Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020). Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. Brain Sciences. https://doi.org/10.3390/brainsci10020105

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.